The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies
Abstract
Summary: The prevalence of hepatitis B virus (HBV) infection in patients with haematological malignancies is increased compared with the general population worldwide. HBV reactivation is common following chemotherapy and is associated with a high mortality despite prompt anti‐viral treatment. HBV reactivation may necessitate interruption of chemotherapy with adverse prognostic consequences for the haematological disease. Chemotherapy‐induced immune suppression may lead to increased HBV replication. Immune reconstitution within the weeks and months following recovery from chemotherapy may be associated with a flare of hepatitis B manifested by hepatocellular injury. Risk factors associated with HBV reactivation include detectable hepatitis B surface antigen (HBsAg), HBV DNA, Hepatitis B e (HBeAg) antigen, antibodies to hepatitis B core antigen (anti‐HBc), treatment with corticosteroids, young age and male gender. Lamivudine is effective during HBV reactivation due to immune suppression. Clinical trials have demonstrated that pre‐emptive antiviral treatment with lamivudine is superior to deferred treatment. Current recommendations emphasise screening for HBV infection in all haematology patients, particularly prior to chemotherapy. Patients who are HBsAg positive or HBV DNA positive should receive pre‐emptive treatment with lamivudine before chemotherapy. The duration of lamivudine treatment may be prolonged commensurate with the degree of immunosuppression. HBV naïve patients should be immunised against hepatitis B, as should haematopoietic stem cell donors. In summary, overt and occult HBV pose a serious, but preventable, threat. Pre‐treatment screening of patients at risk should be practiced diligently by all clinicians that treat patients with malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haine, M. M.-L., & Meeùs, N. (1986) · Cited by 3,464
Lavanchy, D. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00487.x · Cited by 2,642
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Self-citationHepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
Kao, J., Chen, P., Lai, M., & Chen, D. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70261-7 · Cited by 925
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
Lok, A. S. F., Liang, R. H. S., Chiu, E. K. W., Wong, K.-L., Chan, T.-K., & Todd, D. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90599-g · Cited by 827
Yeo, W., Chan, P. K. S., Zhong, S., Ho, W. M., Steinberg, J. L., Tam, J. S., Hui, P., Leung, N. W. Y., Zee, B., & Johnson, P. J. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200011)62:3<299::aid-jmv1>3.0.co;2-0 · Cited by 627
Yim, H. J., & Lok, A. S.-F. (2006) · Hepatology · doi:10.1002/hep.20956 · Cited by 545
Molecular Virology of Hepatitis B Virus
Locarnini, S. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828672 · Cited by 515
Osterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
Cited by
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.001 · Cited by 1,347
Dienstag, J. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801644 · Cited by 961
Statements from the Taormina expert meeting on occult hepatitis B virus infection
Raimondo, G., Allain, J.-P., Brunetto, M. R., Buendia, M.-A., Chen, D.-S., Colombo, M., Craxì, A., Donato, F., Ferrari, C., Gaeta, G. B., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.014 · Cited by 833
Self-citation
Metadata
- Authors
- Lalazar, G., Rund, D., & Shouval, D.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2007-01-08
- Volume
- 136
- Issue
- 5
- Pages
- 699-712
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2119526388
- Cited by
- 311
- References
- 55
- FWCI
- 20.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. https://app.cochat.ai/papers/10.1111/j.1365-2141.2006.06465.x
- The paper
- Lalazar, G., Rund, D., & Shouval, D. (2007). Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2006.06465.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.